In addition, we found that the patients in CR with higher CXCR4 expression (13/33) decreased significantly compared with the lower group (32/51), and our data showed that high CXCR4 expression might prevent the complete remission of AML patients after primary chemotherapy. This evidence concerns the gene CXCR4 and acute myeloid leukemia.